$AHCO

U.S. indexes drifted lower as crude oil and interest rates were mostly flat, with investors awaiting the July CPI report. FactSet data for 88% of S&P 500 firms showed 86% positive earnings surprises and 76% positive revenue surprises. Nasdaq fell 0.6% to 26,445, S&P 500 0.3% to 7,728, Dow 0.3% to 53,791. CoreWeave (CRWV) and Super Micro (SMCI) report after the close; Nvidia (NVDA) and Intel (INTC) were also discussed.

AdaptHealth (AHCO) reported Q2 2026 net revenue of $740.3 million, up 12.7% year over year, with organic revenue growth of 15.9%. Adjusted EBITDA was $132 million, down 3.2%, and full-year revenue guidance was cut to $2.85-$2.89 billion with adjusted EBITDA of $490-$520 million. The company cited West Coast contract costs and a $30 million supplier price headwind, plus a $235 million diabetes divestiture.

AdaptHealth (NASDAQ:AHCO) said it will sell its diabetes unit to focus on sleep and respiratory. The deal is expected to leave about $60 million of overhead costs in continuing operations, with roughly half removed in year one. Q2 revenue grew 16%, including West Coast expansion, while the company works on contract onboarding and supplier rebate terms.

AdaptHealth Corp. (NASDAQ:AHCO) director Kenneth A. Samet bought 23,500 shares on Aug. 6, 2026 at $6.38 each for about $149,930. After the purchase, he beneficially owns 48,569 shares. The stock is near its 52-week low. The company recently reported a Q2 adjusted loss of $0.99 vs a $0.15 expected profit, with revenue of $740.3 million.

SAMET KENNETH A purchased 23,500 shares of AdaptHealth Corp. (AHCO) at $6.38 ($0.15M total) on 2026-08-06.

WOLF DALE B purchased 20,000 indirectly-held shares of AdaptHealth Corp. (AHCO) at $5.86 ($0.12M total) on 2026-08-07.

WOLF DALE B purchased 20,000 shares of AdaptHealth Corp. (AHCO) at $6.37 ($0.13M total) on 2026-08-06.

AdaptHealth (NASDAQ: AHCO) shares fell about 47% this week after the company reported Q2 results below expectations and issued sharply lower guidance. Analysts expected EPS of $0.15; AdaptHealth posted a loss of $1.07 per share. Sales rose 12.7% to $740.3M but missed forecasts. Full-year sales guidance was cut to $2.85B-$2.89B and EBITDA and FCF ranges were reduced.

AdaptHealth Corp. (NASDAQ:AHCO) shares fell about 13% premarket after Q2 2026 results missed expectations and the company cut full-year guidance. It reported a net loss of $0.99 per share and revenue of $740.3M versus $848.9M expected. FY revenue guidance was lowered to $2.85B-$2.89B from about $3.49B, with adjusted EBITDA $490M-$520M and free cash flow $80M-$120M.

The article lists five stocks with large Tuesday moves. AdaptHealth (AHCO) fell 39.5% after weaker Q2 results and a major cut to full-year guidance. UL Solutions (ULS) dropped 11.7% on soft Q2 results. Ball (BALL) fell 3.1% despite a revenue beat. Tidewater (TDW) rose 18.5% on mixed Q2 2026 results. Wayfair (W) gained 27.5% after Q2 revenue and earnings beat estimates.